You Won't Believe What Ysios Capital Just Did with a €100M Fund—Is Your Startup Missing Out?

Ysios Capital, a notable Spanish venture capital firm specializing in life sciences, has made an impactful announcement today with the launch of its new fund, InceptionBio. This fund aims to raise a target of €100 million, focusing primarily on the creation of BioTech companies and the development of early-stage projects. The fund has already achieved a significant milestone, completing its first closing with support from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte program, which is designed to bolster investment in high-potential, innovative companies.

Leading this initiative will be Joan Perelló, the Managing Partner at Ysios Capital, along with partner Arturo Urrios. In a statement, Perelló emphasized Spain's potential, saying, “Spain has world-class science and a unique opportunity to translate that science into globally impactful BioTech companies. With InceptionBio, we aim to further strengthen our ability to engage at the earliest stages of innovation, working closely with the scientific ecosystem to build companies that can deliver meaningful solutions for patients.”

Founded in 2008, Ysios Capital oversees more than €400 million in assets across three venture capital funds. Additionally, the firm acts as an investment advisor to the Telescope Biotech Fund, a publicly listed BioTech fund managed by Andbank Wealth Management. The firm is dedicated to providing private equity funding to early- and mid-stage life science companies that are developing treatments addressing significant unmet medical needs.

InceptionBio will specifically target the identification, development, and establishment of new companies rooted in high-quality scientific advancements, predominantly within Spain. This includes a focus on technology transfer opportunities and early-stage enterprises. By collaborating closely with universities, research centers, and scientific entrepreneurs, Ysios aims to accelerate the conversion of scientific discoveries into viable therapies.

The support from CDTI-Innvierte not only enhances public-private collaboration but also plays a crucial role in Spain’s BioTech landscape, facilitating the acceleration of technology transfer and fostering the growth of innovation-driven companies. According to Ysios Capital, this collaboration is essential for boosting the competitiveness of Spain’s R&D system.

Currently, the fund is reviewing a pipeline of investment opportunities and has set an ambitious goal of supporting the creation of at least three new BioTech companies by 2026. The strategy includes establishing new companies based on scientific assets from universities and research centers, while also identifying and attracting international assets that can be developed within Spain.

Arturo Urrios highlighted the broader vision for InceptionBio, stating, “We see a significant opportunity to identify differentiated scientific assets, translate them into high-potential companies, and attract the talent and capital needed to develop them. InceptionBio was created to connect science, entrepreneurship and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain.”

Ysios Capital has a robust track record, having invested in more than 40 BioTech companies and completing six exits on NASDAQ as well as ten mergers and acquisitions. The firm has actively participated in significant transactions in the Spanish BioTech sector, including key investments in notable firms such as Tigenix/Cellerix, Sanifit, STAT-Diagnostica, Ona Therapeutics, SpliceBio, and Minoryx Therapeutics. Their involvement has also included substantial deals like the €450 million acquisition of Tigenix by Takeda, Qiagen's purchase of STAT-Diagnostica for €172 million, and Vifor Pharma’s acquisition of Sanifit worth €375 million.

The launch of InceptionBio represents not just a financial investment, but a strategic commitment to nurturing the BioTech ecosystem in Spain. By creating a bridge between scientific research and entrepreneurship, Ysios Capital is poised to play a significant role in shaping the future of BioTech innovation in a country known for its scientific excellence.